Janux Therapeutics (JANX)

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

的Janux Therapeutics, Inc. Common Stock（JANX）股票的价格今天是$13.37，自市场开启。该公司市值为$8.04亿，日交易量为$877.00股。前一交易日收盘价为 $13.45。

您准备好开始了吗？按照以下步骤操作，或阅读我们关于在Kraken上从10美元起购买Janux Therapeutics股票的指南。